dexamethasone + methotrexate + fluorouracil + doxorubicin + thiotepa

This drug is a combination chemotherapy regimen consisting of **dexamethasone**, **methotrexate**, **fluorouracil (5-FU)**, **doxorubicin**, and **thiotepa**. Each agent acts via a different mechanism to inhibit cancer cell growth and division: - **Dexamethasone** is a synthetic glucocorticoid used for its anti-inflammatory and immunosuppressive effects, often included as supportive care to reduce inflammation, suppress immune responses, and prevent chemotherapy-induced nausea and vomiting. - **Methotrexate** is an antimetabolite that inhibits dihydrofolate reductase, interfering with DNA and RNA synthesis. - **Fluorouracil (5-FU)** is a pyrimidine analog antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. - **Doxorubicin** is an anthracycline antibiotic that intercalates into DNA, inhibits topoisomerase II, and generates free radicals, leading to DNA breaks and apoptosis. - **Thiotepa** is an alkylating agent that crosslinks DNA strands, preventing replication and transcription. The combination targets cancer through multiple mechanisms and is highly cytotoxic, primarily employed in aggressive malignancies. This specific combination as named is not found as a standard regimen in current literature, but similar combinations are used in high-dose chemotherapy protocols for certain cancers, sometimes as part of conditioning regimens before stem cell or bone marrow transplantation.